Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination

► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels w...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 31; no. 9; pp. 1293 - 1297
Main Authors Paulke-Korinek, Maria, Kundi, Michael, Laaber, Brigitte, Brodtraeger, Natascha, Seidl-Friedrich, Claudia, Wiedermann, Ursula, Kollaritsch, Herwig
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 18.02.2013
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels were significantly higher in subjects reporting any kind of allergy. ► A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster. In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.
AbstractList In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.
► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels were significantly higher in subjects reporting any kind of allergy. ► A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster. In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.
In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n=178) and 10 years (n=183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.
Highlights ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels were significantly higher in subjects reporting any kind of allergy. ► A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster.
Highlights * Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. * Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. * Antibody levels were significantly lower in subjects starting at the age of 50 years. * Antibody levels were significantly higher in subjects reporting any kind of allergy. * A single booster dose was highly effective in subjects who lost protective antibody titers 10 years post-booster.
In a sample of originally 430 healthy adults (18a84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative seroprotection rates 8 (n = 178) and 10 years (n = 183) after the last booster dose were 86.8% and 77.3% according to the neutralization test, respectively. In subjects aged 50 years and older, antibody titers were significantly lower compared to subjects younger than 50 years. History of any allergy but not previous exposure to other flaviviral antigens was associated with higher neutralization titers. In subjects with waning immunity, a single booster dose induced a strong anamnestic antibody response.
Author Brodtraeger, Natascha
Kollaritsch, Herwig
Kundi, Michael
Seidl-Friedrich, Claudia
Paulke-Korinek, Maria
Laaber, Brigitte
Wiedermann, Ursula
Author_xml – sequence: 1
  givenname: Maria
  surname: Paulke-Korinek
  fullname: Paulke-Korinek, Maria
  organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
– sequence: 2
  givenname: Michael
  surname: Kundi
  fullname: Kundi, Michael
  organization: Institute of Environmental Health, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
– sequence: 3
  givenname: Brigitte
  surname: Laaber
  fullname: Laaber, Brigitte
  organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
– sequence: 4
  givenname: Natascha
  surname: Brodtraeger
  fullname: Brodtraeger, Natascha
  organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
– sequence: 5
  givenname: Claudia
  surname: Seidl-Friedrich
  fullname: Seidl-Friedrich, Claudia
  organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
– sequence: 6
  givenname: Ursula
  surname: Wiedermann
  fullname: Wiedermann, Ursula
  organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
– sequence: 7
  givenname: Herwig
  surname: Kollaritsch
  fullname: Kollaritsch, Herwig
  email: herwig.kollaritsch@meduniwien.ac.at
  organization: Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Kinderspitalgasse 15, A-1090 Vienna, Austria
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27110613$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/23306371$$D View this record in MEDLINE/PubMed
BookMark eNqNkl9rFDEUxQep2G31I6gDIviya_5MJhmKihSrQsGHVvAtZDI3bbYzyZpkVvbbm-luKSzICoH78rvnntx7Tooj5x0UxUuMFhjh-v1ysVZaWwcLgjBZ5Ic4e1LMsOB0ThgWR8UMkbqaVxj9Oi5OYlwihBjFzbPimFCKasrxrBgulE4-xFLF6LVVCbryj023ZYTg7TCMzqZNqW6UdTGVyeq7svXBQQlOw-pW9TbZWK5tGGOJUbkBNWmZBCFzPk5161Ml693z4qlRfYQXu3paXF98uT7_Nr_88fX7-efLua4JSfOu0w3h0DbAW-BVTZmgRovOdECwBtSYhmFuOkLalqtacW06ZLgRjPGqBXpavNvKroL_PUJMcrBRQ98rB36MEtei5qSpMDuM0kpUDaooOowSUTdVVfFJ9c0euvRjcPnLeTZhDRWkaTL1akeN7QCdXAU7qLCRD9fJwNsdoKJWvQnKaRsfOY4xqjHN3NmW08HHGMBIbdP9wlNQtpcYySkzcil3mZFTZrJhie7Nsr3uhwGH-l5v-4zyUt2E7OznVQYYQpgLJkgmPm0JyLdeWwgyajsFp7MBdJKdtwdnfNxT0L11Ni_jDjYQH7cqY26QV1Pip8DjLCJylrLAh38L_IeBvx3oEVc
CODEN VACCDE
CitedBy_id crossref_primary_10_1371_journal_pone_0247216
crossref_primary_10_1016_j_vaccine_2014_01_072
crossref_primary_10_1111_ene_13356
crossref_primary_10_1093_femspd_ftu002
crossref_primary_10_1016_j_tmaid_2020_101876
crossref_primary_10_1017_S0950268821000194
crossref_primary_10_1080_21645515_2015_1093263
crossref_primary_10_1371_journal_pone_0257721
crossref_primary_10_1371_journal_pone_0100860
crossref_primary_10_3390_vaccines10081294
crossref_primary_10_7774_cevr_2025_14_e8
crossref_primary_10_1080_21645515_2020_1757990
crossref_primary_10_1093_cid_ciz176
crossref_primary_10_3389_fimmu_2024_1352720
crossref_primary_10_31631_2073_3046_2018_17_5_78_88
crossref_primary_10_33442_978_981_14_0914_1_14
crossref_primary_10_31631_2073_3046_2016_15_2_72_76
crossref_primary_10_1016_j_ttbdis_2013_06_001
crossref_primary_10_1016_j_ttbdis_2021_101779
crossref_primary_10_31631_2073_3046_2025_24_1_31_41
crossref_primary_10_1016_j_vaccine_2016_07_029
crossref_primary_10_1371_journal_pone_0140545
crossref_primary_10_1016_j_vaccine_2015_05_037
crossref_primary_10_1016_j_vaccine_2015_12_057
crossref_primary_10_1586_14760584_2015_985661
crossref_primary_10_1002_jmv_25316
crossref_primary_10_1016_j_vaccine_2018_03_076
crossref_primary_10_18821_0507_4088_2018_63_1_36_40
crossref_primary_10_21101_cejph_a5271
crossref_primary_10_1128_JCM_02680_13
crossref_primary_10_33442_26613980_14_6
crossref_primary_10_1016_j_antiviral_2019_01_014
crossref_primary_10_1136_bmjopen_2022_061228
crossref_primary_10_1016_j_vaccine_2022_01_022
crossref_primary_10_1016_j_vaccine_2013_05_093
crossref_primary_10_1016_j_ttbdis_2013_04_005
crossref_primary_10_33442_26613980_14_5
crossref_primary_10_33442_26613980_14_4
Cites_doi 10.1111/j.1399-3038.2005.00331.x
10.1099/vir.0.031641-0
10.1007/s10354-010-0758-5
10.1111/j.1469-0691.2012.03944.x
10.1016/j.vaccine.2008.08.056
10.1016/S0140-6736(98)05104-6
10.1586/erv.12.86
10.1016/j.vaccine.2007.08.024
10.1016/j.vaccine.2004.07.002
10.1016/j.vaccine.2005.01.085
10.1016/j.idc.2008.03.013
10.1016/0264-410X(91)90315-W
10.1586/14760584.7.5.589
10.1128/JVI.00080-06
10.1016/j.vaccine.2011.07.089
10.1016/j.vaccine.2009.09.068
10.1016/j.vaccine.2006.06.037
10.1371/journal.pone.0034145
10.1002/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I
10.1046/j.1365-2249.1997.4311446.x
10.1016/j.vaccine.2007.01.116
10.1016/S0264-410X(02)00819-8
10.1093/infdis/jir122
10.4161/hv.5.8.8571
10.1016/S0264-410X(02)00813-7
10.1111/j.0105-2896.2006.00403.x
10.2807/ese.14.36.19325-en
10.1016/j.vaccine.2008.11.082
10.1016/j.vaccine.2006.01.007
10.1016/j.vaccine.2006.08.044
10.2807/ese.13.26.18916-en
10.1016/j.vaccine.2004.01.041
ContentType Journal Article
Copyright 2013 Elsevier Ltd
Elsevier Ltd
2014 INIST-CNRS
Copyright © 2013 Elsevier Ltd. All rights reserved.
Copyright Elsevier Limited Feb 18, 2013
Copyright_xml – notice: 2013 Elsevier Ltd
– notice: Elsevier Ltd
– notice: 2014 INIST-CNRS
– notice: Copyright © 2013 Elsevier Ltd. All rights reserved.
– notice: Copyright Elsevier Limited Feb 18, 2013
DBID FBQ
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7RV
7T2
7T5
7U9
7X7
7XB
88C
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M0T
M1P
M2O
M7N
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
7S9
L.6
DOI 10.1016/j.vaccine.2012.12.075
DatabaseName AGRIS
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Nursing & Allied Health Database
Health and Safety Science Abstracts (Full archive)
Immunology Abstracts
Virology and AIDS Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database (Proquest)
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
ProQuest SciTech Premium Collection
Consumer Health Database
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Consumer Health Database
Health & Medical Collection (Alumni)
Healthcare Administration Database (Proquest)
Proquest Medical Database
ProQuest Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
Health & Safety Science Abstracts
ProQuest Public Health
ProQuest Central Basic
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList AGRICOLA

MEDLINE - Academic


Research Library Prep
MEDLINE

AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
– sequence: 4
  dbid: FBQ
  name: AGRIS
  url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Veterinary Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2518
EndPage 1297
ExternalDocumentID 3500387671
23306371
27110613
10_1016_j_vaccine_2012_12_075
US201500178582
S0264410X12018622
1_s2_0_S0264410X12018622
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Austria
Europe
GeographicLocations_xml – name: Austria
– name: Europe
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
53G
5RE
5VS
7-5
71M
7RV
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABKYH
ABMAC
ABMZM
ABRWV
ABUWG
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEUYN
AEVXI
AEXOQ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGGSO
AGUBO
AGYEJ
AHMBA
AIEXJ
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AQUVI
AXJTR
AZQEC
BBNVY
BENPR
BHPHI
BKEYQ
BKNYI
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CJTIS
CNWQP
CS3
DWQXO
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HMCUK
IHE
J1W
K9-
KOM
L7B
LK8
LUGTX
LW9
M0R
M0T
M1P
M29
M2O
M41
M7P
MO0
N9A
NAPCQ
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
Q38
ROL
RPZ
SAB
SCC
SDF
SDG
SDP
SES
SNL
SPCBC
SSH
SSI
SSZ
T5K
UKHRP
UV1
WH7
WOW
Z5R
~G-
.GJ
29Q
3V.
AACTN
AAQXK
ACRPL
ADMUD
ADNMO
ADVLN
AFCTW
AFJKZ
AFKWA
AGHFR
AHHHB
AJOXV
ALIPV
AMFUW
ASPBG
AVWKF
AZFZN
FEDTE
FGOYB
G-2
HEJ
HLV
HMG
HMK
HMO
HVGLF
HX~
HZ~
R2-
RIG
SAE
SEW
SIN
SVS
WUQ
XPP
ZGI
ZXP
AAIAV
ABLVK
ABYKQ
AESVU
AJBFU
EFLBG
LCYCR
QYZTP
ABPIF
ABPTK
FBQ
AAYXX
ACMHX
ADSLC
AGQPQ
AGRNS
AGWPP
AIGII
APXCP
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T5
7U9
7XB
8FK
C1K
H94
K9.
M7N
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
7S9
L.6
ID FETCH-LOGICAL-c622t-ddc927eb9e7be7463583fc8dfde21ce09f9517fd22bb7a6a7cfd0f7f85574be3
IEDL.DBID 7X7
ISSN 0264-410X
1873-2518
IngestDate Fri Jul 11 16:24:16 EDT 2025
Fri Jul 11 01:59:29 EDT 2025
Tue Aug 05 09:32:51 EDT 2025
Wed Aug 13 04:13:54 EDT 2025
Mon Jul 21 06:05:47 EDT 2025
Mon Jul 21 09:15:27 EDT 2025
Tue Jul 01 03:38:02 EDT 2025
Thu Apr 24 23:06:01 EDT 2025
Wed Dec 27 19:27:02 EST 2023
Fri Feb 23 02:26:53 EST 2024
Sun Feb 23 10:19:12 EST 2025
Tue Aug 26 17:46:42 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords Booster properties
Long-term
Antibody persistence
Tick borne encephalitis
Immunization schedule
Follow-up
Nervous system diseases
Immunization
Antibody
Booster vaccination
Vaccine
Flavivirus
Cerebral disorder
Infection
Tick borne encephalitis group virus
Virus
Viral disease
Arbovirus disease
Central nervous system disease
Flaviviridae
Tick borne encephalitis virus
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
Copyright © 2013 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c622t-ddc927eb9e7be7463583fc8dfde21ce09f9517fd22bb7a6a7cfd0f7f85574be3
Notes http://dx.doi.org/10.1016/j.vaccine.2012.12.075
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 23306371
PQID 1625938299
PQPubID 105530
PageCount 5
ParticipantIDs proquest_miscellaneous_1686729415
proquest_miscellaneous_1348490430
proquest_miscellaneous_1286944475
proquest_journals_1625938299
pubmed_primary_23306371
pascalfrancis_primary_27110613
crossref_citationtrail_10_1016_j_vaccine_2012_12_075
crossref_primary_10_1016_j_vaccine_2012_12_075
fao_agris_US201500178582
elsevier_sciencedirect_doi_10_1016_j_vaccine_2012_12_075
elsevier_clinicalkeyesjournals_1_s2_0_S0264410X12018622
elsevier_clinicalkey_doi_10_1016_j_vaccine_2012_12_075
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-02-18
PublicationDateYYYYMMDD 2013-02-18
PublicationDate_xml – month: 02
  year: 2013
  text: 2013-02-18
  day: 18
PublicationDecade 2010
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
– name: Netherlands
PublicationTitle Vaccine
PublicationTitleAlternate Vaccine
PublicationYear 2013
Publisher Elsevier Ltd
Elsevier
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
– name: Elsevier Limited
References Plentz, Jilg, Schwarz, Kuhr, Zent (bib0065) 2009; 27
Weinberger, Grubeck-Loebenstein (bib0125) 2012; 18
Fomsgaard A, Christiansen C, Bodker R. First identification of tick-borne encephalitis in Denmark outside of Bornholm. Euro Surveill 2009;14(36):pii=19325. Available from
Jelenik, Keller, Briggs, Günther, Haglund, Hudeckova (bib0045) 2010; 160
Kaml, Weiskirchner, Keller, Luft, Hoster, Hasford (bib0100) 2006; 24
Kunz (bib0035) 2003; 21
Heinz, Holzmann, Essl, Kundi (bib0040) 2007; 25
Loew-Baselli, Poellabauer, Pavlova, Fritsch, Firth, Petermann (bib0110) 2011; 29
Mansfield, Horton, Johnson, Li, Barrett, Smith (bib0155) 2011; 92
World Health Organization (bib0030) 2011; 24
Klockmann, Bock, Kwasny, Praus, Cihlová, Tomková (bib0095) 1991; 9
Süss (bib0015) 2008; 13.
Rendi-Wagner, Shouval, Genton, Lurie, Rumke, Boland (bib0140) 2006; 24
Rendi-Wagner, Kundi, Zent, Banzhoff, Jaehnig, Stemberger (bib0070) 2004; 23
Prescott, Macaubas, Smallacombe, Holt, Sly, Holt (bib0165) 1999; 353
Hainz, Jenewein, Asch, Pfeiffer, Berger, Grubeck-Loebenstein (bib0105) 2005; 23
Orlinger, Hofmeister, Fritz, Holzer, Falkner, Unger (bib0150) 2011; 203
Rendi-Wagner, Paulke-Korinek, Kundi, Wiedermann, Laaber, Kollaritsch (bib0075) 2007; 25
Paulke-Korinek, Rendi-Wagner, Kundi, Laaber, Wiedermann, Kollaritsch (bib0060) 2009; 27
Holzmann, Kundi, Stiasny, Clement, McKenna, Kunz (bib0085) 1996; 48
Blanco-Quiros, Garcia-Marcos, Garrote, Martinez-Torres, Leon (bib0160) 2005; 16
Schuller, Klade, Heinz, Kollaritsch, Rendi-Wagner, Jilma (bib0145) 2008; 26
Stiasny, Kiermayr, Holzmann, Heinz (bib0080) 2006; 80
Kaiser (bib0010) 2008; 22
Holzmann (bib0130) 2003; 21
[accessed 15.10.12].
Loew-Baselli, Poellabauer, Pavlova, Fritsch, Koska, Bobrovsky (bib0115) 2009; 5
Kreil, Burger, Bachmann, Fraiss, Eibl (bib0090) 1997; 110
Stiasny, Aberle, Keller, Grubeck-Loebenstein, Heinz (bib0120) 2012; 7
Rendi-Wagner, Kundi, Zent, Dvorak, Jaehnig, Holzmann (bib0050) 2004; 22
Abbas, Lichtman, Pillai (bib0170) 2007
Schosser, Kaiser, Mansmann, Heininger (bib0055) 2009
Lanzavecchia, Bernasconi, Traggiai, Ruprecht, Corti, Sallusto (bib0175) 2006; 211
Kollaritsch, Paulke-Korinek, Holzmann, Hombach, Bjorvatn, Barrett (bib0020) 2012; 11
Rendi-Wagner, Korinek, Winkler, Kundi, Kollaritsch, Wiedermann (bib0135) 2007; 25
Rendi-Wagner (bib0005) 2008; 7
Loew-Baselli (10.1016/j.vaccine.2012.12.075_bib0115) 2009; 5
Blanco-Quiros (10.1016/j.vaccine.2012.12.075_bib0160) 2005; 16
10.1016/j.vaccine.2012.12.075_bib0025
Lanzavecchia (10.1016/j.vaccine.2012.12.075_bib0175) 2006; 211
Schosser (10.1016/j.vaccine.2012.12.075_bib0055) 2009
Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0005) 2008; 7
Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0140) 2006; 24
Plentz (10.1016/j.vaccine.2012.12.075_bib0065) 2009; 27
Kollaritsch (10.1016/j.vaccine.2012.12.075_bib0020) 2012; 11
Prescott (10.1016/j.vaccine.2012.12.075_bib0165) 1999; 353
Jelenik (10.1016/j.vaccine.2012.12.075_bib0045) 2010; 160
Klockmann (10.1016/j.vaccine.2012.12.075_bib0095) 1991; 9
Holzmann (10.1016/j.vaccine.2012.12.075_bib0085) 1996; 48
Abbas (10.1016/j.vaccine.2012.12.075_bib0170) 2007
Orlinger (10.1016/j.vaccine.2012.12.075_bib0150) 2011; 203
Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0050) 2004; 22
Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0135) 2007; 25
Mansfield (10.1016/j.vaccine.2012.12.075_bib0155) 2011; 92
Stiasny (10.1016/j.vaccine.2012.12.075_bib0080) 2006; 80
Heinz (10.1016/j.vaccine.2012.12.075_bib0040) 2007; 25
Holzmann (10.1016/j.vaccine.2012.12.075_bib0130) 2003; 21
Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0075) 2007; 25
Paulke-Korinek (10.1016/j.vaccine.2012.12.075_bib0060) 2009; 27
Kunz (10.1016/j.vaccine.2012.12.075_bib0035) 2003; 21
Kreil (10.1016/j.vaccine.2012.12.075_bib0090) 1997; 110
Stiasny (10.1016/j.vaccine.2012.12.075_bib0120) 2012; 7
Rendi-Wagner (10.1016/j.vaccine.2012.12.075_bib0070) 2004; 23
Süss (10.1016/j.vaccine.2012.12.075_bib0015) 2008; 13.
Kaiser (10.1016/j.vaccine.2012.12.075_bib0010) 2008; 22
Kaml (10.1016/j.vaccine.2012.12.075_bib0100) 2006; 24
Weinberger (10.1016/j.vaccine.2012.12.075_bib0125) 2012; 18
Schuller (10.1016/j.vaccine.2012.12.075_bib0145) 2008; 26
World Health Organization (10.1016/j.vaccine.2012.12.075_bib0030) 2011; 24
Hainz (10.1016/j.vaccine.2012.12.075_bib0105) 2005; 23
Loew-Baselli (10.1016/j.vaccine.2012.12.075_bib0110) 2011; 29
References_xml – volume: 27
  start-page: 7027
  year: 2009
  end-page: 7030
  ident: bib0060
  article-title: Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection
  publication-title: Vaccine
– volume: 21
  start-page: S50
  year: 2003
  end-page: S55
  ident: bib0035
  article-title: TBE vaccination and the Austrian experience
  publication-title: Vaccine
– volume: 23
  start-page: 3232
  year: 2005
  end-page: 3235
  ident: bib0105
  article-title: Insufficient protection for healthy elderly adults by tetanus and TBE vaccines
  publication-title: Vaccine
– volume: 23
  start-page: 427
  year: 2004
  end-page: 434
  ident: bib0070
  article-title: Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation
  publication-title: Vaccine
– volume: 18
  start-page: 100
  year: 2012
  end-page: 108
  ident: bib0125
  article-title: Vaccines for the elderly
  publication-title: Clin Microbiol Infect
– volume: 11
  start-page: 1103
  year: 2012
  end-page: 1119
  ident: bib0020
  article-title: Vaccines and vaccination against tick-borne encephalitis
  publication-title: Expert Rev Vaccines
– volume: 29
  start-page: 7307
  year: 2011
  end-page: 7319
  ident: bib0110
  article-title: Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme
  publication-title: Vaccine
– volume: 203
  start-page: 1556
  year: 2011
  end-page: 1564
  ident: bib0150
  article-title: A tick-borne encephalitis vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans
  publication-title: J Infect Dis
– volume: 25
  start-page: 927
  year: 2007
  end-page: 931
  ident: bib0135
  article-title: Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population
  publication-title: Vaccine
– year: 2009
  ident: bib0055
  article-title: Seropositivity before and seroprotection after a booster vaccination with FSME-Immun adults in subjects with a time interval of >4.5 years since the last TBE vaccination
  publication-title: International Jena Symposium on Tick Borne Diseases
– volume: 353
  start-page: 196
  year: 1999
  end-page: 200
  ident: bib0165
  article-title: Development of allergen-specific T-cell memory in atopic and normal children
  publication-title: Lancet
– volume: 25
  start-page: 5097
  year: 2007
  end-page: 5101
  ident: bib0075
  article-title: Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up
  publication-title: Vaccine
– volume: 26
  start-page: 6151
  year: 2008
  end-page: 6156
  ident: bib0145
  article-title: Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51
  publication-title: Vaccine
– reference: Fomsgaard A, Christiansen C, Bodker R. First identification of tick-borne encephalitis in Denmark outside of Bornholm. Euro Surveill 2009;14(36):pii=19325. Available from:
– volume: 25
  start-page: 7559
  year: 2007
  end-page: 7567
  ident: bib0040
  article-title: Field effectiveness of vaccination against tick-borne encephalitis
  publication-title: Vaccine
– volume: 211
  start-page: 303
  year: 2006
  end-page: 309
  ident: bib0175
  article-title: Understanding and making use of human memory B cells
  publication-title: Immunol Rev
– volume: 13.
  year: 2008
  ident: bib0015
  article-title: Tick-borne encephalitis in Europe and beyond—the epidemiological situation as of 2007
  publication-title: Euro Surveill
– volume: 80
  start-page: 9557
  year: 2006
  end-page: 9568
  ident: bib0080
  article-title: Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites
  publication-title: J Virol
– volume: 24
  start-page: 6808
  year: 2006
  end-page: 6811
  ident: bib0100
  article-title: Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers
  publication-title: Vaccine
– volume: 92
  start-page: 2821
  year: 2011
  end-page: 2829
  ident: bib0155
  article-title: Flavivirus-induced antibody cross-reactivity
  publication-title: J Gen Virol
– reference: [accessed 15.10.12].
– year: 2007
  ident: bib0170
  article-title: Cellular and molecular immunology
– volume: 7
  start-page: e34145
  year: 2012
  ident: bib0120
  article-title: Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis
  publication-title: PLoS ONE
– volume: 24
  start-page: 2781
  year: 2006
  end-page: 2789
  ident: bib0140
  article-title: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine
  publication-title: Vaccine
– volume: 21
  start-page: S36
  year: 2003
  end-page: S40
  ident: bib0130
  article-title: Diagnosis of tick-borne encephalitis
  publication-title: Vaccine
– volume: 9
  start-page: 42
  year: 1991
  end-page: 46
  ident: bib0095
  article-title: Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization
  publication-title: Vaccine
– volume: 110
  start-page: 358
  year: 1997
  end-page: 361
  ident: bib0090
  article-title: Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages
  publication-title: Clin Exp Immunol
– volume: 22
  start-page: 561
  year: 2008
  end-page: 575
  ident: bib0010
  article-title: Tick-borne encephalitis
  publication-title: Infect Dis Clin North Am
– volume: 22
  start-page: 2743
  year: 2004
  end-page: 2749
  ident: bib0050
  article-title: Persistence of protective immunity following vaccination against tick-borne encephalitis—longer than expected?
  publication-title: Vaccine
– volume: 48
  start-page: 102
  year: 1996
  end-page: 107
  ident: bib0085
  article-title: Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis
  publication-title: J Med Virol
– volume: 160
  start-page: 247
  year: 2010
  end-page: 251
  ident: bib0045
  article-title: Congress report: tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne Encephalitis (ISW-TBE)
  publication-title: Wien Med Wochenschr
– volume: 27
  start-page: 853
  year: 2009
  end-page: 856
  ident: bib0065
  article-title: Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults
  publication-title: Vaccine
– volume: 24
  start-page: 241
  year: 2011
  end-page: 256
  ident: bib0030
  article-title: Vaccines against tick-borne encephalitis: WHO position paper
  publication-title: WER
– volume: 5
  start-page: 551
  year: 2009
  end-page: 556
  ident: bib0115
  article-title: Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5
  publication-title: Hum Vaccines
– volume: 7
  start-page: 589
  year: 2008
  end-page: 596
  ident: bib0005
  article-title: Advances in vaccination against tick-borne encephalitis
  publication-title: Expert Rev Vaccines
– volume: 16
  start-page: 637
  year: 2005
  end-page: 640
  ident: bib0160
  article-title: Antibody levels to
  publication-title: Pediatr Allergy Immunol
– volume: 16
  start-page: 637
  issue: 8
  year: 2005
  ident: 10.1016/j.vaccine.2012.12.075_bib0160
  article-title: Antibody levels to Bordetella pertussis in 10-yr-old children with atopy and atopic asthma
  publication-title: Pediatr Allergy Immunol
  doi: 10.1111/j.1399-3038.2005.00331.x
– volume: 92
  start-page: 2821
  issue: Pt 12
  year: 2011
  ident: 10.1016/j.vaccine.2012.12.075_bib0155
  article-title: Flavivirus-induced antibody cross-reactivity
  publication-title: J Gen Virol
  doi: 10.1099/vir.0.031641-0
– volume: 160
  start-page: 247
  issue: 9–10
  year: 2010
  ident: 10.1016/j.vaccine.2012.12.075_bib0045
  article-title: Congress report: tick-borne encephalitis and golden agers: position paper of the International Scientific Working Group on Tick-borne Encephalitis (ISW-TBE)
  publication-title: Wien Med Wochenschr
  doi: 10.1007/s10354-010-0758-5
– volume: 18
  start-page: 100
  issue: S5
  year: 2012
  ident: 10.1016/j.vaccine.2012.12.075_bib0125
  article-title: Vaccines for the elderly
  publication-title: Clin Microbiol Infect
  doi: 10.1111/j.1469-0691.2012.03944.x
– volume: 26
  start-page: 6151
  issue: 48
  year: 2008
  ident: 10.1016/j.vaccine.2012.12.075_bib0145
  article-title: Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.08.056
– volume: 353
  start-page: 196
  issue: 9148
  year: 1999
  ident: 10.1016/j.vaccine.2012.12.075_bib0165
  article-title: Development of allergen-specific T-cell memory in atopic and normal children
  publication-title: Lancet
  doi: 10.1016/S0140-6736(98)05104-6
– volume: 11
  start-page: 1103
  issue: 9
  year: 2012
  ident: 10.1016/j.vaccine.2012.12.075_bib0020
  article-title: Vaccines and vaccination against tick-borne encephalitis
  publication-title: Expert Rev Vaccines
  doi: 10.1586/erv.12.86
– volume: 25
  start-page: 7559
  issue: 43
  year: 2007
  ident: 10.1016/j.vaccine.2012.12.075_bib0040
  article-title: Field effectiveness of vaccination against tick-borne encephalitis
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.08.024
– volume: 23
  start-page: 427
  issue: 4
  year: 2004
  ident: 10.1016/j.vaccine.2012.12.075_bib0070
  article-title: Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2004.07.002
– volume: 23
  start-page: 3232
  issue: 25
  year: 2005
  ident: 10.1016/j.vaccine.2012.12.075_bib0105
  article-title: Insufficient protection for healthy elderly adults by tetanus and TBE vaccines
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2005.01.085
– volume: 22
  start-page: 561
  issue: 3
  year: 2008
  ident: 10.1016/j.vaccine.2012.12.075_bib0010
  article-title: Tick-borne encephalitis
  publication-title: Infect Dis Clin North Am
  doi: 10.1016/j.idc.2008.03.013
– volume: 9
  start-page: 42
  issue: 1
  year: 1991
  ident: 10.1016/j.vaccine.2012.12.075_bib0095
  article-title: Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization
  publication-title: Vaccine
  doi: 10.1016/0264-410X(91)90315-W
– volume: 7
  start-page: 589
  issue: 5
  year: 2008
  ident: 10.1016/j.vaccine.2012.12.075_bib0005
  article-title: Advances in vaccination against tick-borne encephalitis
  publication-title: Expert Rev Vaccines
  doi: 10.1586/14760584.7.5.589
– volume: 80
  start-page: 9557
  issue: 19
  year: 2006
  ident: 10.1016/j.vaccine.2012.12.075_bib0080
  article-title: Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites
  publication-title: J Virol
  doi: 10.1128/JVI.00080-06
– volume: 29
  start-page: 7307
  issue: 43
  year: 2011
  ident: 10.1016/j.vaccine.2012.12.075_bib0110
  article-title: Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2011.07.089
– volume: 27
  start-page: 7027
  issue: 50
  year: 2009
  ident: 10.1016/j.vaccine.2012.12.075_bib0060
  article-title: Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2009.09.068
– volume: 24
  start-page: 6808
  issue: 47–48
  year: 2006
  ident: 10.1016/j.vaccine.2012.12.075_bib0100
  article-title: Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.06.037
– volume: 7
  start-page: e34145
  issue: 3
  year: 2012
  ident: 10.1016/j.vaccine.2012.12.075_bib0120
  article-title: Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0034145
– volume: 48
  start-page: 102
  issue: 1
  year: 1996
  ident: 10.1016/j.vaccine.2012.12.075_bib0085
  article-title: Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis
  publication-title: J Med Virol
  doi: 10.1002/(SICI)1096-9071(199601)48:1<102::AID-JMV16>3.0.CO;2-I
– volume: 110
  start-page: 358
  issue: 3
  year: 1997
  ident: 10.1016/j.vaccine.2012.12.075_bib0090
  article-title: Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages
  publication-title: Clin Exp Immunol
  doi: 10.1046/j.1365-2249.1997.4311446.x
– volume: 24
  start-page: 241
  issue: 86
  year: 2011
  ident: 10.1016/j.vaccine.2012.12.075_bib0030
  article-title: Vaccines against tick-borne encephalitis: WHO position paper
  publication-title: WER
– volume: 25
  start-page: 5097
  issue: 27
  year: 2007
  ident: 10.1016/j.vaccine.2012.12.075_bib0075
  article-title: Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.01.116
– volume: 21
  start-page: S36
  issue: Suppl. 1
  year: 2003
  ident: 10.1016/j.vaccine.2012.12.075_bib0130
  article-title: Diagnosis of tick-borne encephalitis
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(02)00819-8
– volume: 203
  start-page: 1556
  issue: 11
  year: 2011
  ident: 10.1016/j.vaccine.2012.12.075_bib0150
  article-title: A tick-borne encephalitis vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jir122
– year: 2009
  ident: 10.1016/j.vaccine.2012.12.075_bib0055
  article-title: Seropositivity before and seroprotection after a booster vaccination with FSME-Immun adults in subjects with a time interval of >4.5 years since the last TBE vaccination
– volume: 5
  start-page: 551
  issue: 8
  year: 2009
  ident: 10.1016/j.vaccine.2012.12.075_bib0115
  article-title: Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5ml in adults aged 18–67 years
  publication-title: Hum Vaccines
  doi: 10.4161/hv.5.8.8571
– volume: 21
  start-page: S50
  issue: S 1
  year: 2003
  ident: 10.1016/j.vaccine.2012.12.075_bib0035
  article-title: TBE vaccination and the Austrian experience
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(02)00813-7
– volume: 211
  start-page: 303
  year: 2006
  ident: 10.1016/j.vaccine.2012.12.075_bib0175
  article-title: Understanding and making use of human memory B cells
  publication-title: Immunol Rev
  doi: 10.1111/j.0105-2896.2006.00403.x
– ident: 10.1016/j.vaccine.2012.12.075_bib0025
  doi: 10.2807/ese.14.36.19325-en
– volume: 27
  start-page: 853
  issue: 6
  year: 2009
  ident: 10.1016/j.vaccine.2012.12.075_bib0065
  article-title: Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.11.082
– volume: 24
  start-page: 2781
  issue: 15
  year: 2006
  ident: 10.1016/j.vaccine.2012.12.075_bib0140
  article-title: Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.01.007
– volume: 25
  start-page: 927
  issue: 5
  year: 2007
  ident: 10.1016/j.vaccine.2012.12.075_bib0135
  article-title: Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.08.044
– year: 2007
  ident: 10.1016/j.vaccine.2012.12.075_bib0170
– volume: 13.
  issue: 26
  year: 2008
  ident: 10.1016/j.vaccine.2012.12.075_bib0015
  article-title: Tick-borne encephalitis in Europe and beyond—the epidemiological situation as of 2007
  publication-title: Euro Surveill
  doi: 10.2807/ese.13.26.18916-en
– volume: 22
  start-page: 2743
  issue: 21–22
  year: 2004
  ident: 10.1016/j.vaccine.2012.12.075_bib0050
  article-title: Persistence of protective immunity following vaccination against tick-borne encephalitis—longer than expected?
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2004.01.041
SSID ssj0005319
Score 2.2331774
Snippet ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and...
Highlights ► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were...
In a sample of originally 430 healthy adults (18–84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative...
In a sample of originally 430 healthy adults (18-84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative...
Highlights * Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. * Cumulative seroprotection rates were...
In a sample of originally 430 healthy adults (18a84 years of age) with documented basic and booster immunization against tick borne encephalitis, cumulative...
SourceID proquest
pubmed
pascalfrancis
crossref
fao
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1293
SubjectTerms Adolescent
Adult
adults
Age
Age Factors
Aged
Allergies
Allergy and Immunology
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
Antibody persistence
antigens
Applied microbiology
Arachnids
Arboviral encephalitis
Arboviroses
Biological and medical sciences
Booster properties
Encephalitis
Encephalitis Viruses, Tick-Borne - immunology
Female
Fever
Follow-up
Fundamental and applied biological sciences. Psychology
Human viral diseases
Humans
hypersensitivity
Immune system
immunity
Immunization schedule
Immunologic Memory
Infectious diseases
Ixodidae
Long-term
Male
Medical sciences
Microbiology
Middle Aged
Miscellaneous
neutralization
neutralization tests
Population
secondary immunization
Studies
Tick borne encephalitis
ticks
Time Factors
Tropical viral diseases
Vaccination - methods
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viral diseases
Viral infections
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Virology
viruses
Young Adult
SummonAdditionalLinks – databaseName: Elsevier ScienceDirect
  dbid: .~1
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGJBAvCMrHAmMyEtrT0iaOEzuPaKKakECT1qG-WXZij2yQVk07qS_87dw5ScvE2BBSn9o71_Fd7n6274OQ9yBIHRvY5GSOFyG4AB3qtNQhx2ZwjEWSa1_t80t2cs4_TdPpDjnuc2EwrLKz_a1N99a6-2bUreZoXlWjs8j78mgagw8DXI52mHOBWj78-VuYR-KbeyBxiNTbLJ7R5fBaF3h9jRFezJ8KYrjh7f7pgdMzDJzUDayda5te_B2Veu80fkqedLCSfmhn_ozs2HpAHraNJtcD8uhzd4U-IIenbbHq9RGdbHOvmiN6SE-3ZayBZ_AVI2V8ui7t2Z-TH-O2QQ_VnVxtSfEsl4IqzyqfbLJcU32hK8CdFEa-oqBltaW4svNviPqrhl5Xi1VD44iu4UWDsbBROdBhwsmCtsvlNeYFmYw_To5Pwq5lQ1iABJZhWRY5E9bkVhgrOKAZmbhClq60LC5slDtAdMKVjBkjdKZF4crICSfTVHBjk5dkt57Vdo_QXAKWMCA2m8c81YW2iRF5xDWMoZ1hAeG9nFTRlTPHrhrfVR-3dqk68SoUr4IPiDcgww3bvK3ncR9D1iuB6pNVwbwq8Dj3MYrbGG3TGYlGxaoBSvWHIgdEbjhvvAv_8qd7oKdKX4CHUOdnDM-zwObKVMKoBzeUd_P4TMR4LpAEZL_XZrWdI-6PEwmgJSDvNj-DCcJ7JV3b2QpomMxyjpUj76BJuOQ5Fpi7gyaTGez1AFIG5FX7Nm0nmcDeNhHx6_9fmzfkMfO9TFgYy32yu1ys7FtAlEtz4E3GL-EXczo
  priority: 102
  providerName: Elsevier
Title Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X12018622
https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X12018622
https://dx.doi.org/10.1016/j.vaccine.2012.12.075
https://www.ncbi.nlm.nih.gov/pubmed/23306371
https://www.proquest.com/docview/1625938299
https://www.proquest.com/docview/1286944475
https://www.proquest.com/docview/1348490430
https://www.proquest.com/docview/1686729415
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfoJhAvCMrHCqMyEtrT0sWOEztPaEyrCoiqYh3qm-Uk9uiAtjTtpL7wt3OXj0ZIo0Oq0krxuU7ufP75fB-EvAVGGpbAJidyIvVgCTCeCTPjCSwGx7mvhCmyfQ6jwaX4OAknlcEtr9wqa51YKOpsnqKN_IQhUA8UaM93i18eVo3C09WqhEaL7GPqMnTpkhPZuHgERWEP2GYITzB_0kTwnFz3bkyKR9fo3cULiyC6Gt6-NrWcmaPTpMnhvbmy4MW_EWmxMvUfk0cVpKSnpQw8IffsrE3ul0UmN23y4HN1fN4mR6MyUfXmmI6buKv8mB7RUZPCGmjaX9FLpgjVpTX5U_KzXxbnoabiqc0o2nEpiPF8WgSarDbUXJkpYE4KPX-nIGEzS1F7LL4h4p_m9Ga6XOeU-XQDkwz6wiLl0A6DTZa0fF2FtDwj4_75-GzgVeUavDTifOVlWRpzaZPYysRKAUhGBS5VmcssZ6n1YwdoTrqM8ySRJjIydZnvpFNhKEVig-dkbzaf2QNCYwU4IgG22ZiJ0KTGBomMfWGgD-MS3iGi5pNOq1TmWFHjh6591q51xV6N7NXwAfZ2SG9LtihzedxFENVCoOtAVVCtGlabuwjlbYQ2rxRErpnOoaW-8AtA6k8YUMPmEh5NbSkrDFRim__50wOQU22uYHXQlxccbVmgb1WooNfuX8K7fXwuGdoEgg45rKVZN2PcTrkOebO9DeoHz5TMzM7X0IarKBaYNXJHm0AoEWNyuR1tIhXBPg_gZIe8KGdTM8gA9rWBZC93D_IVeciLWiXcY-qQ7K2Wa_saEOMq6ZJW7zfrFsoBruoMfu-ffvg0GML3-_Ph6MsfqqduJA
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9tnfh4QVA-VhjDSLCnZYsdJ3YeEOJjVce2qmId6pvlJM7ogLY07VD_KP5HzvlohDQ6XiblrT7H6Z3vw767H8ArZKSmEQY5QcpjB02AdrSfaIdbMDjGXMl13u2zG3TO-KeBP1iD31UtjE2rrHRirqiTcWzPyPepddQ9idrz7eSnY1Gj7O1qBaFRiMWRWfzCkC17c_gR-fuasfZB_0PHKVEFnDhgbOYkSRwyYaLQiMgIjgZXemkskzQxjMbGDVN0OkSaMBZFQgdaxGnipiKVvi94ZDycdh02uIeRTAM23h90e5_rnBIvRxLBuIY7nLqDumRo_2LvUsf2rtymk7H8CNLmNl5tDNdTPbZZmjpDRqUFwsa_XeDcFLbvw73ShyXvCqF7AGtm1IRbBarlogm3T8r7-ibs9IrO2Itd0q8LvbJdskN6dc9spGl-sWk5eW0wqcgfwo92gQZEdClEJiH24JjgvhkP88qW2YLocz1EJ5fgzN8IivTIEKuuJl9tiDHMyOVwOs8IdckC2YdzWVR0HGerW6ak-Lty8XwE_Zvg5GNojMYjswkklOi4RMg2E1Lu61gbLxKhyzXOodOItYBXfFJx2TvdQnh8V1WS3IUq2assexU-yN4W7C3JJkXzkOsIgkoIVFUZi7pcoXm7jlBcRWiyUiNliqoMR6pTN_eA3QFFaoxm8dPkkrJ0ugpn6n9euolyqvQ5miN1dsrs4RkqeOlLnHX7L-Fdfj4T1B5CeC3YqqRZ1Wtc7vEWvFz-jPrOXmLpkRnPcQyTQchtm8oVYzwueWi72a0YE8gAA0v0X1vwpNhN9SI9DKQ9QZ-uXuQLuNPpnxyr48Pu0TO4y3KgFOZQuQWN2XRunqO7Oou2SyVBQN2wWvoDx06pTg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe2ISZeEBTYCmMYCfa0rLHjxM4DQohRbQymSutQ3ywnsUcHtKVph_qn8d9xl49GSKPjZVLf6nPt3vk-7Lv7EfIKGGlYAkFO5ETqgQkwngkz4wkEg-PcV8IU3T5Po6Nz8XEQDtbI77oWBtMqa51YKOpsnOIdeYehox4o0J4dV6VF9A67byc_PUSQwpfWGk6jFJETu_gF4Vv-5vgQeP2a8-6H_vsjr0IY8NKI85mXZWnMpU1iKxMrBRhfFbhUZS6znKXWjx04INJlnCeJNJGRqct8J50KQykSG8C06-SOhH3hEZMD2WSXBAWmCEQ4whPMHzTFQ53LgyuT4qs5Jpbx4jISsxyvN4vrzowxX9PkwDJXYm382xkujGL3AblfebP0XSl-D8maHbXI3RLfctEim5-rl_sW2euVPbIX-7TflHzl-3SP9pru2UDT-oIJOkWVMK3JH5Ef3RIXiJpKnGxG8QqZwgkaD4sal9mCmgszBHeXwszfKAj3yFJUXJOvGGwMc3o1nM5zyny6AObBXIiPDuOwzmVKy7-rENTHpH8bfHxCNkbjkd0mNFbgwiTANhszEZrU2CCRsS8MzGFcwttE1HzSadVFHcE8vus6Xe5SV-zVyF4NH2BvmxwsySZlG5GbCKJaCHRdIwtaXYOhu4lQXkdo80o35ZrpHEbqM7_whf0BA2qIa2FraklZuV-lW_U_P7oNcqrNBRgmfX7G8RoNVL0KFcy6-5fwLrfPJcPriKBNdmpp1s0al6e9TV4uvwbNh89ZZmTHcxjDVRQLbFi5YkwglIixr92KMZGKIMQET7ZNtsrT1CwygJA6kOzp6kW-IJugjPSn49OTZ-QeLxBTuMfUDtmYTef2Ofits2S30BCU6FvWSH8AlkOsHg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+associated+with+seroimmunity+against+tick+borne+encephalitis+virus+10+years+after+booster+vaccination&rft.jtitle=Vaccine&rft.au=PAULKE-KORINEK%2C+Maria&rft.au=KUNDI%2C+Michael&rft.au=LAABER%2C+Brigitte&rft.au=BRODTRAEGER%2C+Natascha&rft.date=2013-02-18&rft.pub=Elsevier&rft.issn=0264-410X&rft.volume=31&rft.issue=9&rft.spage=1293&rft.epage=1297&rft_id=info:doi/10.1016%2Fj.vaccine.2012.12.075&rft.externalDBID=n%2Fa&rft.externalDocID=27110613
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X13X00076%2Fcov150h.gif